Catalyst in the News

Featured News11/09 — The American Journal of Psychiatry (PDF)
Editorial (PDF) A team including Catalyst Scientific Advisors Brodie, Dewey, and Laska reported positive results for Catalyst's 2007 Phase II trial in Mexico. The paper concludes that vigabatrin may be safe and effective in the treatment of cocaine addiction.

11/13/08 — SynapseSynapse reports that vigabatrin, which Catalyst is testing as an addiction treatment, blocks reinstatement of drug-seeking behavior in animals, giving hope for treating relapse to methamphetamine abuse.
8/20/08 — SynapseSynapse reports that genetically bred “fat rats” given vigabatrin, which Catalyst is testing as an addiction treatment, experience dramatic weight loss.
3/3/08 — Newsweek (PDF version) Cover story: "What Addicts Need: Addiction isn't a weakness; it's an illness. Now vaccines and other new drugs may change the way we treat it."

12/18/07 — Rodman & Renshaw, transcript (PDF)
Rodman & Renshaw rates Catalyst "Market Outperform" and sponsors expert panel on the promise of vigabatrin to treat addiction.
12/07 — The Ones to Watch (PDF)
In its quarterly review, Thomson Scientific calls CPP-109 one of "the five most promising drugs entering Phase II trials" from July to September 2007. See page 7
07/16/07 — BioCentury
"Product Development: Down-sizing the High"
07/05/07 — TIME magazine
"How We Get Addicted"
02/16/07 — Long Island Newsday
"Dulling dopamine's kick"
01/14/07 — Miami Herald
"Catalyst focuses on drug to treat addicts"

04/21/05 — Senate Testimony
Nora D. Volkow, MD, Director of NIDA, discusses promise of CPP-109 during "Methamphetamine Abuse – Testimony before the Senate Subcommittee on Labor, Health and Human Services, Education, and Related Agencies – Committee on Appropriations"

12/10/04 — VentureWire Lifescience
"Catalyst Looks for $10M Series B as it Plans Clinical Trials"
02/15/04 — NIDA Notes"The Long Road to Medication Development: Cocaine Treatment Moves to Clinical Trials"